Our stock price may be volatile; and our stockholders investment in our stock could decline in value. The trading price of our common stock is likely to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors; including adverse results or delays in preclinical testing or clinical trials inability to obtain additional funding any delay in filing an IND or NDA for any of our future product candidates an any adverse development or perceived adverse development with respect to the FDA s review of that IND or NDA failure to maintain our existing collaborations or enter into new collaborations failure of our collaboration partners to elect to develop or commercialize product candidates under our collaboration agreements or the termination of any programs under our collaboration agreements failure by us or our licensors and collaboration partners to prosecute; maintain or enforce our intellectual property rights failure to successfully develop and commercialize our future product candidates changes in laws or regulations applicable to future products inability to obtain adequate product supply for our future product candidates or the inability to do so at acceptable prices adverse regulatory decisions introduction of new products; services or technologies by our competitors failure to meet or exceed financial projections we may provide to the public failure to meet or exceed the estimates and projections of the investment community the perception of the pharmaceutical industry by the public; legislatures; regulators and the investment community 56 Table of Contents Index to Financial Statements announcements of significant acquisitions; strategic partnerships; joint ventures or capital commitments by us; our collaboration partners or our competitors disputes or other developments relating to proprietary rights; including patents; litigation matters and our ability to obtain patent protection for our technologies additions or departures of key scientific or management personnel significant lawsuits; including patent or stockholder litigation changes in the market valuations of similar companies sales of our common stock by us or our stockholders in the future and trading volume of our common stock. In addition; companies trading in the stock market in general have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock; regardless of our actual operating performance.